ROTIGOTINE ARROW 8 mg/24 hours, medicated transdermal patch 30 patches in individual sachets
Active ingredients: (6S)-rotigotine
Commercialized according to BDPMDispensing in France: Prescription only
Medicated transdermal patch30 patches in individual sachetstransdermique
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ROTIGOTINE ARROW 8 mg/24 heures, dispositif transdermique
- Pharmaceutical form
- dispositif
- Route of administration
- transdermique
- Presentation description
- 30 sachets-doses copolymère d'éthylène aluminium polyéthylène basse densité (PEBD) papier polyéthylène de 1 dispositif
- Marketing authorisation holder
- ARROW GENERIQUES
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Apr 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63205730CIP73027833CIP133400930278338Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ROTIGOTINEdispositif | 17,72 mg · un dispositif | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.